Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
16.40 ^USD	-3.76%		-1.86%	-23.79%

04/03	NervGen Pharma Corp. Announces Executive Changes	CI
04/03	Sarepta Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM

Analyst Reco.

02/03	Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating	MT
23/01	Wedbush Raises Price Target on Sarepta Therapeutics to $34 From $32, Keeps Outperform Rating	MT
08/01	RBC Raises Price Target on Sarepta Therapeutics to $18 From $16, Keeps Sector Perform, Speculative Risk	MT
10/12	Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says	MT
09/12	Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says	MT
06/11	Sarepta Therapeutics Shares Rise After Mizuho Upgrade	MT
05/11	Mizuho Securities Upgrades Sarepta Therapeutics to Outperform From Neutral, Adjusts PT to $26 From $19	MT
22/25/22	BofA Securities Adjusts Sarepta Therapeutics Price Target to $18 From $16, Maintains Underperform Rating	MT
08/25/08	RBC Raises Price Target on Sarepta Therapeutics to $16 From $14, Keeps Sector Perform, Speculative Risk	MT
22/25/22	BMO Capital Upgrades Sarepta Therapeutics to Outperform From Market Perform, Price Target is $50	MT
20/25/20	BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating	MT
15/25/15	Sarepta Therapeutics Still Faces Elevidys Demand Uncertainty, Deutsche Bank Says	MT
15/25/15	Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $12 From $6, Maintains Sell Rating	MT
15/25/15	Analyst recommendations: Amgen, Applied Materials, Cisco, Nvidia, Oracle…
29/25/29	Barclays Upgrades Sarepta Therapeutics to Equalweight From Underweight, Raises Price Target to $22 From $10	MT
29/25/29	Sarepta Therapeutics Set to Trade Higher With Elevidys Back on Market, Oppenheimer Says	MT
29/25/29	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Market Perform, Adjusts Price Target to $37 From $30	MT
29/25/29	JPMorgan Upgrades Sarepta Therapeutics to Neutral From Underweight, Price Target is $24	MT
29/25/29	Morgan Stanley Raises Price Target on Sarepta Therapeutics to $20 From $15, Keeps Equalweight Rating	MT
28/25/28	JPMorgan Downgrades Sarepta Therapeutics to Underweight From Neutral	MT
28/25/28	Barclays Downgrades Sarepta Therapeutics to Underweight From Equalweight, Adjusts Price Target to $10 From $18	MT
28/25/28	Swiss stocks - Factors to watch on July 28	RE
25/25/25	Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $6 From $9, Maintains Sell Rating	MT
23/25/23	BofA Downgrades Sarepta Therapeutics to Underperform From Neutral, Price Target is $10	MT
22/25/22	Barclays Downgrades Sarepta Therapeutics to Equalweight From Overweight, Adjusts Price Target to $18 From $32	MT